Swiss antibody specialist Memo Therapeutics AG has added CHF20m to its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
https://european-biotechnology.com/wp-content/uploads/2024/06/Decoy_cell_cytology.png541939Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-05-08 15:50:012024-07-08 11:26:02Memo Therapeutics AG increases Series C financing to CHF45m